Malignant News and Research

RSS

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

The primitive stem cell state we created is called an “induced pluripotent stem cell” (iPSC). iPSC are a new, unique, and artificially-created type of stem cell that were first described in 2006 by a Japanese scientist named Shinya Yamanaka.

4 Sep 2012

New drug combines photothermia and chemotherapy to help fight cancer

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

3 Sep 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

31 Aug 2012

Quest Diagnostics announces availability of TERC test for cervical cancer

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer.

From Quest Diagnostics 31 Aug 2012

Endoscopic microsurgery effective for giant rectal adenomas

Transanal endoscopic microsurgery on large rectal adenomas provides results comparable to or better than those reported for alternative techniques, shows a UK study.

29 Aug 2012

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

29 Aug 2012

Scientists identify genes that underlie growth of primitive leukemia stem cells

University of Rochester Medical Center scientists believe they are the first to identify genes that underlie the growth of primitive leukemia stem cells, and then to use the new genetic signature to identify currently available drugs that selectively target the rogue cells.

29 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Renal denervation improves blood pressure and arterial stiffness in patients with therapy resistant hypertension, according to research presented at ESC Congress 2012 by Mr Klaas Franzen from the University Hospital of Schleswig-Holstein.

28 Aug 2012

Control of siRNA could aid regenerative medicine, cancer therapy

Some of the body's own genetic material, known as small interfering RNA (siRNA), can be packaged then unleashed as a precise and persistent technology to guide cell behavior, researchers at Case Western Reserve University report in the current issue of the journal, Acta Biomaterialia.

28 Aug 2012

Patients tend to have worse outcomes when GBM appears in more than one location

When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.

27 Aug 2012

PHF20 transcriptional factor plays a unique role in regulating p53

Researchers at Moffitt Cancer Center and colleagues have identified PHF20, a novel transcriptional factor, and clarified its role in maintaining the stability and transcription of p53, a gene that allows for both normal cell growth and tumor suppression. PHF20, the researchers found, plays a previously unknown and unique role in regulating p53.

24 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

New model more effective in predicting individuals at high risk of lung cancer

A lung cancer risk prediction model developed by scientists at the University of Liverpool has been shown to be a viable tool for selecting high risk individuals for prevention and control programmes.

21 Aug 2012

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Genomic deletions promote cancer by carving up or eliminating tumor-suppressor genes, but now scientists report in the journal Nature that the collateral damage they inflict on neighboring genes exposes cancer cells to vulnerabilities and new avenues for attack.

16 Aug 2012

Malignant mesothelioma diagnosis with an E-nose: an interview with Associate Professor Deborah Yates, UNSW

Malignant mesothelioma is a rare tumor of the pleura which is the lining of the inside of the chest wall. It is highly linked with asbestos exposure.

16 Aug 2012

Inhibiting over-production of Panx1 protein can treat melanoma

New research from Western University, Canada, has identified a potential new target for the treatment of melanoma, the deadliest of all skin cancers. Silvia Penuela and Dale Laird discovered a new channel-forming protein called Pannexin (Panx1) that is expressed in normal levels on the surface of healthy skin cells.

16 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Malignant News and Research

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

Converting blood cells to a stem cell state: an interview with Elias Zambidis, M.D., Ph.D.

New drug combines photothermia and chemotherapy to help fight cancer

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Quest Diagnostics announces availability of TERC test for cervical cancer

Endoscopic microsurgery effective for giant rectal adenomas

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Scientists identify genes that underlie growth of primitive leukemia stem cells

Eplerenone shown to reduce cumulative heart failure hospitalisations

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Control of siRNA could aid regenerative medicine, cancer therapy

Patients tend to have worse outcomes when GBM appears in more than one location

PHF20 transcriptional factor plays a unique role in regulating p53

New results describe development of DC cancer vaccine with enhanced immunogenic potential

New model more effective in predicting individuals at high risk of lung cancer

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Malignant mesothelioma diagnosis with an E-nose: an interview with Associate Professor Deborah Yates, UNSW

Inhibiting over-production of Panx1 protein can treat melanoma

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News